31 results about "Oxymetazoline" patented technology

Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

This invention is directed to pharmaceutical compositions and methods of treating varicose veins, including telangiectasias and reticular veins, and related symptoms and diseases. Embodiments comprise injection into a varicose vein of an amphiphilic block copolymer which has properties of conversion from liquid to gel state, surfactant properties, or combinations thereof. Other embodiments consist of the combination of an amphiphilic block copolymer with a co-solvent, also allowing the injected combination to form a gel within the vein. In other embodiments, an amphiphilic block copolymer is combined with a co-solvent, a sclerosant, a vasoconstrictor, water, or combinations thereof. Other embodiments of the invention include a combination of a sclerosant such as sodium tetradecyl sulfate or polidocanol with a vasoconstrictor, preferably a long-acting vasoconstrictor such as oxymetazoline. Other embodiments are directed to compositions and methods of treating venous and arteriovenous malformations and cancer.

Aqueous nasal spray compositions comprising a medicament and an aqueous carrier comprising water soluble polymers selected from the group consisting of polyvinylpyrrolidone and mixtures thereof.

The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.

Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

The invention relates to a method of treating erythema and / or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and / or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.

The present invention relates to stable liquid formulations of ketoprofen, amitriptyline, and oxymetazoline.

The invention discloses a compound nasal inhalation gel preparation for treating rhinitis. The compound nasal inhalation gel preparation is prepared from, by weight, 0.2-0.3% of levofloxacin, 0.05-0.75% of hyaluronic acid, 0.025-0.05% of oxymetazoline, 0.8-1.0% of lysozyme, 0.025-0.05% of dexamethasone, 0.6-0.9% of sodium chloride, 8-10% of propylene glycol, 0.8-1.0% of Carbomer, 10-12% of glycerol and the balance purified water. The compound nasal inhalation gel preparation is convenient to use, becomes effective fast, and is free of toxic and side effects. Through scientific matching and reasonable compatibility of medicine materials, the content of effective constituents in the preparation is increased; furthermore, due to the fact that the gel preparation is sprayed onto the nasal mucosa, a unique treatment effect is realized through absorption of capillaries and the nasal mucosa based on the physiological characteristics of the nasal cavity, drug action time is prolonged, and a durable and stable treatment effect is realized.

The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.

The photostability of oxymetazoline in a topical decongestant composition is enhanced by lowering the pH of the composition using a buffer solution.

The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.

The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.

The invention discloses application of oxymetazoline as a special substrate for glucuronyl transferase UGT1A9. The oxymetazoline used as the substrate is subjected to glucuronatation reaction in a biological system, and the elimination quantity of the substrate or the generation quantity of the glucuronatation product in unit time is quantitatively detected to determine the UGT1A9 enzyme activity in the biological system. The oxymetazoline can also be used for evaluating the disposition capacity of the UGT1A9 enzyme for the drugs in the human liver microsome. The oxymetazoline has high UGT metabolizing enzyme selectivity (only metabolized by UGT1A9), thereby preventing the oxymetazoline from being influenced by other metabolizing enzymes when being used as the special substrate. Besides, the glucuronatation of the oxymetazoline has the characteristics of metabolite singleness, and easy detection of the metabolites and the like.

The present invention relates to a biologically and chemically stable xylometazoline and / or oxymetazoline solution containing glycerol and / or sorbitol as adjuvant.

The invention discloses ear drops for treating acute suppurative otitis media and a preparation method, and belongs to the technical field of medicine. The ear drops are prepared from broadleaf holly leaves, crepis rigescens, Chinese mosla herb, donax, souliea vaginata, the seed of Chinese dodder, cottonrose hibiscus, encephalon passeris, martianus dermestoides, the root of Indian abutilon, the root of kudzu vine, amur barberry root and branchlet, chloramphenicol ear drops, oxymetazoline, iodine glycerin and crotamiton. The ear drops have the treatment principle of killing germs, diminishing inflammation, stopping pain and expelling pus, a composition for clearing away heat and toxic materials, relieving swelling and pain, stopping bleeding and cooling blood is selected, traditional Chinese medicine and western medicine combined preparation is achieved, the traditional Chinese medicine effect and western medicine effect are improved at the largest efficiency, the complementary and improving effect is achieved, the medical effect is improved, the ear drops can be attached to cell walls of germs to change permeability, enzyme, coenzyme and metabolic intermediates in germs are exposed outwards, mycoprotein is degenerated, and therefore a sterilization effect is achieved. The ear drops are wide in action range, capable of acting rapidly, strong in effect and extremely good in effect on treating acute suppurative otitis media.

The invention relates to a method of treating erythema and / or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and / or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.

The invention discloses a method for detecting imidazoline drugs in biological fluids for the purpose of criminal investigation, comprising the following steps: biological fluid pretreatment; extraction and detection of imidazoline drugs in biological fluids. Established pretreatment formulations and liquid chromatography-mass spectrometry analysis methods for five common imidazoline drugs in biological fluids, tetrahydrozoline, xylometazoline, naphazoline, antazoline, and oxymetazoline. The average recovery The rate is more than 70%, and the detection limit is less than 1ng / mL.

The present disclosure provides novel formulations for treating foot or hand pain by topically administering a sympathomimetic drug, particularly oxymetazoline, to the skin of the foot or hand.

The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a selective alpha-adrenergic receptor agonist or an anticholinergic agentor a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein the selective alpha-adrenergic receptor agonist or anticholinergic agent is selected from the group consisting of pilocarpine, brimonidine and oxymetazoline, or a pharmaceutically acceptable salt or a stereoisomer thereof, and their uses in the treatment or alleviation of xerostomia, dermal diseases and eye disorders.

The invention belongs to the technical field of traditional Chinese medicine, and concretely relates to traditional Chinese medicine for treating rhinitis and rhinitis powder and rhinitis ointment prepared by the same. The traditional Chinese medicine comprises the following raw materials, by weight: 20 g of Chinese honeylocust abnormal fruits, 5 g of realgar, 4 g of flowers of lily magnolia, 4 gof fruits of siberian cocklebur, 4 g of dahurian angelica roots and 5 g of dandelion. The invention also provides the rhinitis powder and the rhinitis ointment prepared by the traditional Chinese medicine. In modern rhinitis treatment technology, ephedrine with 0.5% low concentration, oxymetazoline and naproxazoline are used to improve the symptom but not cure the symptom, and long-term application of some medicine can easily cause atrophy of nasal mucosa. The traditional Chinese medicine for treating rhinitis and the rhinitis powder and the rhinitis ointment prepared by the same are pure traditional Chinese medicine preparations, get rid of side effects of western medicine, tap the potential of medicine of our country, make full use of traditional Chinese medicine analysis and extractiontechnolody, can be easily utilized by nasal mucosa, have good effects, and has the advantages of low cost, quick effect, high curative effect, no toxic and side effect, safety and convenience.

A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally.

Methods for treating fecal incontinence by administering to a subject in need thereof compositions including oxymetazoline as an active ingredient. Kits including compositions of oxymetazoline suitable for topical application, for the treatment of fecal incontinence.

The invention is effective for the treatment and relief of a cough caused by posterior nasal secretion, using the combination of oxymetazoline and ipratropium. The stated active agents in the combination according to the invention have been used and marketed separately with different uses to those according to the invention. The oxymetazoline is market for eliminating nasal secretion and congestion (blockage), and the ipratropium bromide is marketed for the purpose of dilating the bronchi in asthmatic patients and patients with chronic obstructive pulmonary disease, although it has also be used experimentally for reducing nasal secretion. Both active agents, together or separately, have not yet been used as intranasal antitussives. The cough caused by posterior nasal secretion is the mostcommon cause of a cough in humans of any age, and this invention is effective for the treatment and relief of said symptom.

The present disclosure provides novel formulations for treating foot or hand pain by topically administering a sympathomimetic drug, particularly oxymetazoline, to the skin of the foot or hand.

The present invention relates to stable liquid formulations of ketoprofen, amitriptyline, and oxymetazoline.

The present disclosure provides novel formulations for treating foot or hand pain by topically administering a sympathomimetic drug, particularly oxymetazoline, to the skin of the foot or hand.